Synthetic thiazolidinediones: Potential antidiabetic compounds

Current Organic Chemistry

Volumn 15, Issue 1, 2011, Pages 108-127

  Ortiz, Aurelio ^a   Sansinenea, Estibaliz ^a  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

Antidiabetic compounds; Glitazones; Thiazolidinediones

Indexed keywords

'CURRENT; ANTIDIABETIC; ANTIDIABETIC AGENTS; ANTIDIABETIC COMPOUND; CLINICAL EFFICACY; CLINICAL USE; GLITAZONE; ORAL ANTIDIABETICS; THIAZOLIDINEDIONES; TYPE 2 DIABETES MELLITUS;

EID: 78951492038     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527211793797774     Document Type: Article

References (91)

1. Skyler, J. S. Diabetes mellitus: pathogenesis and treatment strategies. J. Med. Chem., 2004, 47, 4113-4117.
2. Ross, S.A.; Gulve, E.A.; Wang, M. Chemistry and biochemistry of type 2 diabetes. Chem. Rev., 2004, 104, 1255-1282.
3. DeFronzo, R.A.; Bonadonna, R.C.; Ferrannini, E. Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: a balanced overview. Diabetologia, 1992. 35, 389-397.
4. Olefsky, J. M. Treatment of insulin resistance with peroxisome proliferators-activated receptor agonists. J. Clin. Invest., 2000, 106, 467-472.
5. Saltiel, A. R.; Olefsky, J. M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 1996, 45, 1661-1669.
6. Schoonjans, K.; Auwers, J. Thiazolidinediones: an update. Lancet, 2000, 355, 1008-1010.
7. Mudaliar, S.; Henry, R. R. New oral therapies for type 2 diabetes mellitus: The Glitazones or Insulin Sensitizers. Ann. Rev. Med., 2001, 52, 239-257.
8. Diamant, M.; Heine, R. J. Thiazolidinediones in type 2 diabetes mellitus. Drugs, 2003, 63, 1373-1405.
9. Nolan, J.J.; Ludvik, B.; Beerdsen, P.; Joyce, M.; Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med., 1994, 331, 1188-1193.
10. Schwartz, S.; Raskin, P.; Fonseca, V.; Graveline, J. F. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N. Engl. J. Med., 1998, 338, 861-866.
11. Inzucchi, S. E.; Maggs, D.G.; Spollet, G. R.; Page, S. L.; Rife, F. S.; Walton, V.; Schulman, G. I. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med., 1998, 338, 867-872.
12. Plosker, G. L.; Faulds, D. Troglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs, 1999, 57, 409-438.
13. Gale, E. A. Lessons from the glitazones: a story of drug development. Lancet, 2001, 357, 1870-1875.
14. Gale, E. A. Troglitazone: the lesson that nobody learned?. Diabetologia, 2006, 49, 1-6.
15. Murphy, E. J.; Davern, T. J.; Shakil, A. O.; Shick, L.; Masharani, U.; Chow, H.; Freise, C.; Lee, W. M.; Bass, N. M. Troglitazone-induced fulminant hepatic failure. Dig. Dis. Sci., 2000, 45, 549-553.
16. Smith, M. T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol., 2003, 16, 679-687.
17. Yoshioka, T.; Kitazawa, E.; Yamazaki, M.; Hasegawa, K. Thiazolidinedione derivatives, their preparation and compositions containing them. EP 0139421, 1984.
18. Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem., 1989, 32, 421-428.
19. Watt, S. D.; Profitt, J. A.; Corey, E. J.; A reagent for, α, β-reduction of conjugated nitriles. J. Org. Chem., 1975, 40, 127-128.
20. Takebayashi, T.; Onodera, T.; Hasegawa, K.; Fujita, T.; Yoshioka, T. Preparation of benzylidenethiazolidines as lipid peroxide formation inhibitors. EP 454 501, 1991; Chem. Abstr. 1992, 116, 59361k.
21. Reddy, K. A.; Lohray, B. B.; Bhushan, V.; Reddy, A. S.; Rao, N. V. S. M.; Reddy, P. P.; Saibaba, V.; Reddy, N. J.; Suryaprakash, A.; Misra, P.; Vikra-madithyan, R. K.; Rajagopalan, R. Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives. J. Med. Chem., 1999, 42, 3265-3278.
22. Reddy, K. A.; Lohray, B. B.; Bhushan, V.; Bajji, A. C.; Reddy, K. V.; Reddy, P. R.; Krishna, T. H.; Rao, I. N.; Ja-joo, H. K.; Rao, N. V. S. M.; Chakrabarti, R.; Dileepkumar, T.; Rajagopalan, R. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones. J. Med. Chem., 1999, 42, 1927-1940.
23. Scott, J. W.; Cort, W. M.; Harley, H.; Parrish, D. R.; Saucy, G. 6-Hydroxychroman-2-carboxylic acids: Novel antioxidants. J. Am. Oil Chem. Soc., 1974, 51, 200-203.
24. 1) Synthesis of 5-[4-(1-methylcyclohexyl-methoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem. Pharm. Bull., 1982, 30, 3580-3600.
25. Fujita, T.; Sugiyama, Y.; Taketomi, S.; Sohda, T.; Kawamastsu, Y.; Iwatsuka, H.; Suzuoki, Z. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexyl methoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878, U, 63287, ciglitazone), a new antidiabetic agent. Diabetes, 1983, 32, 804-810.
26. Chang, A. Y.; Wyse, B. M.; Gilchrist, B. J.; Peterson, T.; Diani, A. R. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes, 1983, 32, 830-838.
27. Chang, A. Y.; Wyse, B. M.; Gilchrist, B. J. Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice. Diabetes, 1983, 32, 839-845.
28. Williams, D. G.; Deldar, A.; Jordan, W. H.; Gries, C.; Long, G. G.; Dimarchi, R. D. Subchronic toxicity of the thiazolidinedione, tanabe 174, in rat and dog. Diabetes, 1993, 42 (Suppl. 1), 59A (abstr. 186).
29. Deldar, A.; William, G.; Stevenes, C. Pathogenesis of thiazolidinedione induced haemotoxocity in the dog. Diabetes, 1993, 42 (Suppl. 1) 57A (abstr. 179).
30. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y. Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds. Chem. Pharm. Bull., 1982, 30, 3563-3573.
31. Kawamatsu, Y.; Asakawa, H.; Saraie, T.; Imamiya, E.; Nishikawa, K.; Hamuro, Y. Studies on antihyperlipidemic agents. II. Synthesis and biological activities of 2-chloro-3-arylpropionic acids. Arzneim.-Forsch., 1980, 30, 585-589.
32. Kawamatsu, Y.; Asakawa, H.; Saraie, T.; Mizuno, K.; Imamiya, E.; Nishikawa, K.; Hamuro, Y. Studies on antihyperlipidemic agents. III. Synthesis and biological activities of 2-chloro-3-arylpropionic acids containing a quaternary carbon atom. Arzneim.-Forsch., 1980, 30, 751-758.
33. Zask, A.; Jirkovsky, I.; Nowicki, J. W.; McCaleb, M. L. Synthesis and anti-hyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2,4-thiazolidine-diones. J. Med. Chem., 1990, 33, 1418-1423.
34. Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; Merrigan, P.; Kelbaugh, P. L.; Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted dihydrobenzopyran and dihydro-benzofuran thiazolidine-2,4-diones as hypoglycemic agents. J. Med. Chem., 1991, 34, 319-325.
35. Eggler, J.; Holland, G.; Johnson, M.; Volkmann, R. Thiazolidinedione derivatives as hypoglycemics and their preparation. US. Patent 4 738 972; 1988; Chem. Abstr. 1989, 110, 75483h.
36. Clark, D. A. Preparation of (ben-zopyranylmethyl)thiazolidinediones as hypoglycemic and anticholesteremic agents. U.S. Pat. 4 791 125,1988.
37. Clark, D. A.; Goldstein, S. W.; Hulin, B. Hypoglycemic and hypocholesterolemic thiazolidinedione derivatives. EP-332 331 and EP-332 332, 1989.
38. Vilsmeier, A.; Haack, A. Action of phosphorus halides on alkylformanilides. A new method for the preparation of secondary and tertiary p-alkylaminonobenzaldehydes. Chem. Ber., 1927, 60, 119.
39. Rieche, A.; Gross, H.; Hoft, E. α-Haloethers. IV. Synthesis of aromatic aldehydes with dichloromethyl alkyl ethers. Chem. Ber., 1960, 93, 88.
40. Smith, W. E. Formylation of aromatic compounds with hexamethylenetetra-mine and trifluoroacetic acid. J. Org. Chem., 1972, 37, 3972.
41. Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel thiazolidine-2,4-diones as potent euglycemic agents. J. Med. Chem., 1992, 35, 1853-1864.
42. Hulin, B.; Newton, L. S.; Lewis, D. M.; Genereux, P. E.; Gibbs, E. M.; Clark, D. A. Hypoglycemic activity of a series of -alkylthio and -alkoxy carboxylic acids related to ciglitazone. J. Med. Chem., 1996, 39, 3897-3907.
43. Gillies, P. S.; Dunn, C. J. Pioglitazone. Drugs, 2000, 60, 333-343.
44. Sohda, T.; Momose, Y.; Meguro, K.; Kawanatsu, Y.; Sugiyama, Y.; Ikeda, H. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim.-Forsch., 1990, 40, 37-42.
45. Ikeda, H.; Taketomi, S.; Sugiyama, Y.; Shimura, Y.; Sohda, T.; Meguro, K.; Fujita, T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim.-Forsch., 1990, 40, 156-162.
46. Sugiyama, Y.; Taketomi, S.; Shimura, Y.; Ikeda, H.; Fujita, T. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneim.-Forsch., 1990, 40, 263-267.
47. Sugiyama, Y.; Shimura, Y.; Ikeda, H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim.-Forsch., 1990, 40, 436-440.
48. 1 Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull., 1991, 39, 1440-1445.
49. Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. J. Med. Chem., 1992, 35, 2617-2626.
50. Sohda, T.; Ikeda, H.; Meguro, K. Studies on antidiabetic agents. XII.1) Synthesis and activity of the metabolites of (±)-5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (pioglitazone). Chem. Pharm. Bull., 1995, 43, 2168-2172.
51. Tanis, S. P.; Parker, T. T.; Colca, J. R.; Fisher, R. M.; Kletzein, R. F. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglyce-mic agent pioglitazone. J. Med. Chem., 1996, 39, 5053-5063.
52. Carpenter, D. E.; Imbordino, R. J.; Maloney, M. T.; Moeslein, J. A.; Reeder, M. R.; Scott, A. Process development and scale-up of the potential thiazolidinedione antidiabetic candidate PNU-91325. Org. Process Res. Dev., 2002, 6, 721-728.
53. Lés, A.; Pucko, W.; Szelejewski, W. Optimization of the reduction of a 5-benzylidenethiazolidine-2,4-dione derivative supported by the reaction response surface analysis: synthesis of pioglitazone hydrochloride. Org. Process Res. Dev., 2004, 8, 157-162.
54. Kim, Y.; Kang, B.; Jeon, R. Synthesis of polymeric thiazolidinedione and fibrate conjugates. Arch. Pharm. Res., 2008, 31, 148-153.
55. Wagstaff, A. J.; Goa, K. L. Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs, 2002, 62, 1805-1837.
56. Deeks, E. D.; Keam, S. J. Rosiglitazone: A review of its use in type 2 diabetes mellitus. Drugs, 2007, 67, 2747-2779.
57. Cantello, B. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[-(Heterocyclyl-amino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 1994, 37, 3977-3985.
58. Cantello, B. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. L. The synthesis of BRL 49653-a novel and potent antihypergly-cemic agent. Bioorg. Med. Chem. Lett., 1994, 4, 1181-1184.
59. Lohray, B. B.; Bhushan, V.; Rao, B. P.; Madhavan, G. R.; Murali, N.; Rao, K. N.; Reddy, K. A.; Rajesh, B. M.; Reddy, P. G.; Chakrabarti, R.; Vikra-madithyan, R. K.; Rajagopalan, R.; Rao, N. V. S. Mamidi; Jajoo, H. K.; Subramaniam, S. Novel euglycemic and hypolipidemic agents 1. J. Med. Chem., 1998, 41, 1619-1630.
60. Lohray, B. B.; Bhushan, V.; Reddy, A. S.; Rao, B. P.; Reddy, N. J.; Harikishore, P.; Haritha, N.; Vikramadithyan, R. K.; Chakrabarti, R.; Rajagopalan, R.; Katneni, K. Novel euglycemic and hypolipidemic agents. 4. Pyridyl-and quinolinyl-containing thiazolidinediones. J. Med. Chem., 1999, 42, 2569-2581.
61. Oguchi, M.; Wada, K.; Honma, H.; Tanaka, A.; Kaneko, T.; Sakakibara, S.; Ohsumi, J.; Serizawa, N.; Fujiwara, T.; Horikoshi, H.; Fujita, T. Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones. J. Med. Chem., 2000, 43, 3052-3066.
62. Sohda, T.; Mizuno, K.; Kawamatsu, Y. Studies on antidiabetic agents. VI. Asymmetric transformation of (±)-5-[4-(1-methylcyclohexylmethoxy)ben-zyl]-2,4-thiazolidinedione(ciglitazone) with optically active 1-phenylethyl-amines. Chem. Pharm. Bull., 1984, 32, 4460-4465.
63. Cantello, B. C. C.; Eggleston, D. S.; Haigh, D.; Haltiwanger, R. C.; Heath, C. M.; Hindley, R. M.; Jennings, K. R.; Sime, J. T.; Woroniecki, S. R. Facile biocatalytic reduction of the carbon-carbon double bond of 5-benzylidene-thiazolidine-2,4-diones. Synthesis of (±)-5-(4-{2-[methyl(2-pyridyl)amino] ethoxy}benzyl)thiazo-lidine-2,4-dione (BRL 49653), its (R)-(+)-enantiomer and analogs. Chem. Soc., Perkin Trans. 1, 1994, 3319-3324.
64. Parks, D. J.; Tomkinson, N. C. O.; Villeneuve, M. S.; Blanchard, S. G.; Willson, T. M. Differential activity of rosiglitazone enantiomers at PPAR. Bioorg. Med. Chem. Lett., 1998, 8, 3657-3658.
65. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kuro-kawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-. Nature, 1998, 395, 137-143.
66. Momose, Y.; Maekawa, T.; Yamano, T.; Kawada, M.; Odaka, H.; Ikeda, H.; Sohda, T. Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidine-dione derivatives as insulin sensitizers with antidiabetic activities. J. Med. Chem., 2002, 45, 1518-1534.
67. Bharatam, P. V.; Khanna, S. Rapid racemization in thiazolidinediones: A quantum chemical study. J. Phys. Chem. A, 2004, 108, 3784-3788.
68. Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awano, K. (3-Substituted Benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg. Med. Chem. Lett., 1999, 9, 533-538.
69. Wang, Q.; Wang, Q.; Yan, D.; Wang, Z.; Cheng, M. Synthesis of new antidiabetic agent KRP-297. Zhongguo Yiyao Gongye Zazhi., 2003. 34, 313-314.
70. Storr, T.; Mitchell, D.; Buglyó, P.; Thompson, K. H.; Yuen, V. G.; McNeill, J. H.; Orvig, C. Vanadyl-thiazolidinedione combination agents for diabetes therapy. Bioconjug. Chem., 2003, 14, 212-221.
71. Mendoza, G.; Hernández, H.; Quintero, L.; Sosa-Rivadeneyra, M.; Bernès, S.; Sansinenea, E.; Ortiz, A. Synthesis of N-substituted 2,4-thiazolidine-diones from oxazolidinethiones. Tetrahedron Lett., 2005, 46, 7867-7870.
72. Chittiboyina, A. G.; Venkatraman, M. S.; Mizuno, C. S.; Desai, P. V.; Patny, A.; Benson, S. C.; Ho, C. I.; Kurtz, T. W.; Pershadsingh, H.A.; Avery, M.A. Design and synthesis of the first generation of dithiolane thiazolidinedione-and phenylacetic acid-based PPAR agonists. J. Med. Chem., 2006, 49, 4072-4084.
73. Rybczynski, P. J.; Zeck, R. E.; Dudash, J.; Combs, D. W.; Burris, T. P.; Yang, M.; Osborne, M. C.; Chen, X.; Demarest, K. T. Benzoxazinones as PPAR agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model. J. Med. Chem., 2004, 47, 196-209.
74. Upton, R.; Widdowson, P. S.; Ishii, S.; Tanaka, H.; Williams, G. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br. J. Pharmacol., 1998, 125, 1708-1714.
75. Pickavance, L.; Widdowson, P. S.; King, P.; Ishii, S.; Tanaka, H.; Williams, G. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. Br. J. Pharmacol., 1998, 125, 767-770.
76. Reginato, M. J.; Bailey, S. T.; Krakow, S. L.; Minami, C.; Ishii, S.; Tanaka, H.; Lazar, M. A. A potent antidiabetic thiazolidinedione with unique peroxisome proliferators-activated receptor -activating properties. J. Biol. Chem., 1998, 273, 32679-32684.
77. Ueno, H.; Oe, T.; Suehiro, I.; Sekiya, A. Preparation of 5-(benzyloxy-2-naphthyl)methyl-2,4-thiazolidinediones as antidiabetic agents and antihyper-tensives. JP 10139768, 1998.
78. Velussi, M. MCC-555 (Mitsubishi-Tokyo Pharmaceuticals). IDrugs, 2001, 4, 586-589.
79. Sun, L.; Wu, Y.; Zheng, G.; Piao, H. Improvement of synthesis of novel antidiabetic agent MCC-555. Yanbian Daxue Yixue Xuebao., 2006, 29, 172-174.
80. Nakamura, Y.; Satoh, C.; Miyamoto, H.; Kajino H. Process for producing thiazolidinedione compound and production intermediate thereof. EP1894929. WO2006078037, 2006.
81. Kawasaki, T.; Suzuki, N.; Yada, S. Pharmaceutical composition containing thiazolidinedione compound. EP1902713. WO2007007656, 2007.
82. Nakamura, Y.; Satoh, C.; Miyamoto, H.; Kajino, H. Pharmaceutical compositions containing thiazolidinedione compounds, and preparation thereof. JP2008044932, 2008.
83. Ohsumi, J.; Wada, K.; Matsui, Y.; Ogata, T. Preparation of optically active thiazolidin-edione derivative, with high affinity for PPAR. WO2007100027, 2007.
84. Kishi, N.; Nakamura, Y.; Abe, N.; Takebayashi, T. Preparation of intermediates for the synthesis of benzimidazole compounds and process for the preparation threreof. WO2001000570, 2001.
85. Rohatagi, S.; Carrothers, T. J.; Jin, J. Y.; Jusko, W. J.; Khariton, T.; Walker, J.; Truitt, K.; Salazar, D. E. Model-based development of a PPAR agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J. Clin. Pharmacol., 2008, 48, 1420-1429.
86. Schimke, K.; Davis, T. M. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes. Curr. Opin. Invest. Drugs, 2007, 8, 338-344.
87. Davies, S.; Castaner, R.; Bolos, J. Rivoglitazone hydrochloride - PPAR agonist, insulin sensitizer, treatment of diabetes. Drugs Fut., 2008, 33, 926-931.
88. Kim, B. Y.; Ahn, J. B.; Lee, H. W.; Moon, K. S.; Sim, T. B.; Shin, J. S.; Ahn, S. K.; Hong, C. I. Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione de-rivatives. Chem. Pharm. Bull., 2003, 51, 276-285.
89. Kim, B. Y.; Ahn, J. B.; Lee, H. W.; Kang, S. K.; Lee, J. H.; Shin, J. S.; Ahn, S. K.; Hong, C. I.; Yoon, S. S. Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. Eur. J. Med. Chem., 2004, 39, 433-447.
90. Lee, H. W.; Kim, B. Y.; Ahn, J. B.; Kang, S. K.; Lee, J. H.; Shin, J. S.; Ahn, S. K.; Lee, S. J.; Yoon, S. S. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur. J. Med. Chem., 2005, 40, 862-874.
91. Lee, H. W.; Ahn, J. B.; Kang, S. K.; Ahn, S. K.; Ha, D.-C. Process development and scale-up of PPAR/ dual agonist lobeglitazone sulfate (CKD-501). Org. Process Res. Dev., 2007, 11, 190-199.